TY - JOUR
T1 - Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
AU - Alzheimer's Disease Neuroimaging Initiative
AU - Vermunt, Lisa
AU - van Paasen, Alegría J. L.
AU - Teunissen, Charlotte E.
AU - Scheltens, Philip
AU - Visser, Pieter Jelle
AU - Tijms, Betty M.
PY - 2019/6/4
Y1 - 2019/6/4
N2 - OBJECTIVE: To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). METHODS: We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented. RESULTS: Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 ± 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels. CONCLUSION: In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.
AB - OBJECTIVE: To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). METHODS: We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented. RESULTS: Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 ± 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels. CONCLUSION: In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067213324&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31068481
U2 - https://doi.org/10.1212/WNL.0000000000007609
DO - https://doi.org/10.1212/WNL.0000000000007609
M3 - Article
C2 - 31068481
SN - 0028-3878
VL - 92
SP - e2699-e2705
JO - Neurology
JF - Neurology
IS - 23
ER -